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1: Introduction
Polyphenols are considered to be beneficial to health, as their consumption has been inversely related to development of cancer, diabetes and cardiovascular diseases [1, 2] . The hydroxycinnamic acid ferulic acid (FA) is found in rice bran, citrus fruits, banana, beetroot, spinach, cabbage, broccoli, tomatoes, cereals and whole grain products [3] [4] [5] . In these foods, FA is esterified to cell wall polysaccharides, limiting its absorption in the small intestine. In addition, coffee is a major source of FA in the form of chlorogenic acid esters formed between quinic acid and trans-cinnamic acids such as FA, p-coumaric acid and caffeic acid [6] [7] [8] . Upon arrival in the colon, esterase activity of the resident microflora releases FA [5] , followed by conjugation to ferulic acid-4-O-sulfate (FA-sul) and ferulic acid-4-O-glucuronide (FA-glu) during uptake in the intestinal epithelium and passage through the liver [9] . Maximal total plasma FA concentrations can reach 11 µM in rats consuming chow containing 1.5 g/kg FA for 9 days [10] and between ~290 and 800 nM in human volunteers upon coffee consumption [11] [12] [13] . In volunteers consuming tomatoes containing 21-44 mg FA, 4-5% was recovered in urine as unmodified FA, increasing to 11-25% when conjugated FA was included [9], comparable to 2-20% of the excreted FA present as glucuronide or sulfate conjugates after consumption of Pinus maritima extract [14] . When FA was perfused into the rat small intestine, free FA was the major form present in the mesenteric vein (60%), but in aorta, 75% of the FA was conjugated [15] , while only conjugated FA was found in plasma and bile [16] . Peak plasma concentrations of FA-sul upon coffee consumption reached between 76 ± 9 and 226 ± 113 nM [8, 17, 18] . In urine, FA-sul was the predominant form of FA, followed by FA-glu and FA aglycone [11] .
FA consumption reduces the risk of diabetes and cardiovascular diseases, improves lipid metabolism [4, 19, 20] and decreases blood pressure in rat models of hypertension [21] . The ex vivo A C C E P T E D M A N U S C R I P T
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vasorelaxant activity of FA is more pronounced in aortae isolated from hypertensive compared to normotensive rats [22] [23] [24] . However, the biological effects and their underlying mechanisms predicted by such ex vivo experiments with FA may differ from those observed in vivo, because of the metabolic transformation of the parent compound in the liver and during absorption in the gut epithelium. In this study, we have investigated the vasorelaxing effect of both the food-derived aglycone FA and the circulating conjugate FA-sul using mouse saphenous artery, femoral artery and aorta. In addition the influence of FA-sul and FA on blood pressure was measured in anesthetized mice.
2: Materials and methods

2.1: Animals
Male Swiss mice were obtained from Janvier (Saint-Berthevin, France), and soluble guanylate cyclase (sGC) alpha 1 subunit knockout (sGCα 1 (-/-) ) mice and their control mice sGCα 1 (+/+) with a 129SvJ background [25] were obtained from the department of Biomedical Molecular Biology (VIB, Ghent, Belgium). The animals were kept in an acclimatised room and food and water were provided ad libitum. All animals were treated in accordance to the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health. This study was approved by the local ethical committee for animal experiments.
2.2: Tissue preparation and mounting
On the day of the experiment, animals (age 8-13 weeks) were sacrificed by cervical dislocation. bubbled with carbogen gas whilst replacing the KRB solution every 10 minutes. After equilibration,
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isolated femoral and saphenous arteries were set to their normalised internal diameter by progressive stretching. The passive passive wall tension, based on internal diameter measurements obtained during progressive stretching, was used to adjust the arterial diameter to 90% of the diameter the vessel would have under a transmural pressure of 100 mmHg [26] . Aortic rings were stretched gradually until a stable preload of 0.5 g was obtained.
2.3: Experimental protocol for isometric tension recordings
After the equilibration period (30 min) at the optimized resting tension, femoral and saphenous arteries were repeatedly activated by treatment with KRB solution containing 120 mM K + and 5 µM phenylephrine (Phe), after which tissues were rinsed with KRB solution until a stable baseline tension was reached. Aortas were contracted once with KRB solution containing 120 mM K + and 1 µM Phe for 15 min, after which the organ baths were rinsed until a stable baseline tension was reached. In sGCα 1 (-/-) mice femoral arteries, the efficiency of sGC was tested by cumulative concentration-response curves (10 -9 -10 -4 M) of sodium nitroprusside (SNP), a nitric oxide (NO)donor. In knockout mice, the response toward SNP was decreased compared to the effect in wild type mice, confirming effective knockout of sGC. To evaluate the presence of functional endothelium, arteries were exposed to 10 µM acetylcholine (Ach). Only arteries containing functional endothelium, as indicated by sudden relaxation upon Ach treatment, were used. Fully functional vessels were rinsed with KRB solution and baseline tension was maintained for 30 min whilst refreshing the KRB solution every 5 minutes. Arteries were contracted with Phe for 30 min (femoral/saphenous) or 1h (aorta) until a stable contraction was reached, after which cumulative concentration-response (1.10 -7 -3.10 -5 M) curves for FA and FA-sul were established, exposing the tissues in 10 min intervals. FA-sul (90%) was synthesized by Dr. Nikolai U. Kraut (University of Leeds, Leeds, UK). Polyphenol stocks were prepared in a concentration of 10 -2 M in 10% DMSO in distilled water. Appropriate dilutions of DMSO were used as control and vehicle concentrations in the organ baths never exceeded 0.1%.
2.4: Mechanistic investigation
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By use of specific modulators added 20 min prior to the final contraction with Phe, the mechanism of FA-sul mediated vasorelaxations was investigated. The NO synthase blocker N G -nitro-L-arginine methyl ester (L-NAME) (100 µM), cyclooxygenase (COX) inhibitor indomethacin (10 µM), sGC inhibitor 1H- [1, 2, 4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ) (10 µM), non-specific K + -channel blocker tetraethyl ammoniumchloride (TEA) (3 mM), small conductance K Ca -channel inhibitor apamin (500 nM), voltage-dependent K + -channel (K v ) inhibitor 4-aminopyridine (4-AP) (3 mM), inward rectifying K + -channel inhibitor Ba 2+ (10 µM) and the ATP sensitive K + -channel inhibitor glibenclamide (3 µM) were used in this study. Glibenclamide was dissolved in DMSO; TEA, apamin, 4-AP, BaCl 2 , L-NAME in distilled water and indomethacin and ODQ in ethanol. Incubation with KRB solution containing 120 mM K + and 3 mM TEA resulted in significantly higher Pheinduced contraction levels. Endothelium was removed by gently rubbing the intimal surface with a stainless steel wire (aorta and femoral artery) or a hair (saphenous artery). Complete removal of the endothelium was verified by the lack of response toward Ach.
2.5: In vivo study
Swiss mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and placed on a heated blanked to maintain their body temperature at 37°C. A PE-10 tube filled with heparinized saline (25 U/mL) was inserted in the carotid artery and connected to a pressure transducer to measure the mean arterial pressure (MAP). The effect FA and FA-sul (standardized injection volume of 10 µL) on MAP was determined after injection through another PE-10 tube introduced to the jugular vein. Ferulic acid was dosed at 11.42 µg/kg (dose 1), and 114.2 µg/kg (dose 2). For FAsul, doses were 16.13 and 161.3 µg/kg respectively. Appropriate dilutions of vehicle (DMSO) served as controls. Treatments order (DMSO, FA, FA-sul) were randomized and tested sequentially in the same animal, with a total of 4 biological replicates. Between each dose, the cannulas were flushed four times with heparinized saline to remove residual agent.
2.6: Data analysis and statistics
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Data are represented as mean values ± S.E.M.. n represents the number of independent preparations in organ bath experiments or the number of mice used for in vivo experiments. For isometric tension measurements, data is expressed relative to the contraction level induced by Phe in the same preparation before cumulative addition of the compounds. In vivo, the MAP was determined prior to the injection of FA or FA-sul, and at the lowest point obtained after injection.
These values were used to calculate the ∆ MAP.
Normality of data was checked and appropriate statistical tests (Student's t-test or Mann-Whitney U test) were used accordingly. *: p<0.05, **: p<0.01, ***: p<0.001.
3: Results
3.1: Response to FA and FA-sul ex vivo
We compared the vasorelaxing properties of FA and FA-sul in mouse aorta, femoral and saphenous arteries. Within the concentration range tested, FA elicited no significant response. FAsul, however, caused significant concentration-dependent relaxations in all three tissues. The observed E max was 64.2 ± 4.0% in saphenous artery, 89.8 ± 4.5% in femoral artery and 70.7 ± 3.5% in aorta whereas in vehicle controls, tension decreased by 32.8 ± 7.4%, 14.5 ± 13.5% and -15.9 ± 10.5% respectively ( Fig. 1) . Immediate relaxations were observed upon application of a higher concentration of FA-sul ( Fig. 2 ).
To exclude toxicity of FA-sul, tissues were rinsed after FA-sul treatment, maintained at basal resting tension for 20 minutes and contracted with Phe. The successful contraction excluded vasorelaxations due to tissue damage inflicted by FA-sul in our experimental setup (data not shown).
3.3: Response to FA and FA-sul in vivo
In Swiss mice, the basal MAP was 114.1 ± 1.7 mmHg. Immediately after intravenous injection of FA-sul, the MAP decreased significantly by 9.6 ± 1.2 (dose 1) and 34.9 ± 3.2 mm Hg (dose 2) ( 
3.2: Vasorelaxing mechanism
Because previous studies partly attribute FA-mediated vasorelaxation to the endothelium [22, 23] , we investigated the involvement of the endothelium in isolated aorta, femoral and saphenous arteries by mechanic removal and by incubation with L-NAME and indomethacin ( Fig. 4 ). FA-sul induced relaxation was not attenuated by these treatments, thereby excluding the endothelium as an active participant in FA-sul-mediated vasorelaxation. Endothelium denudation and L-NAME treatment further amplified vasorelaxation upon FA-sul treatment, although the effect was only significant in aorta and femoral arteries respectively ( Fig. 4 A,B ,C,G,H,I).
Even though the endothelium was not involved, a direct effect of FA-sul on sGC could not be ruled out and was further investigated by incubation with the sGC inhibitor ODQ ( Fig. 5 A for femoral artery, data for aorta and saphenous artery not shown). ODQ strongly decreased FA-sul-induced relaxations, indicating involvement of sGC in the three arteries. The vasorelaxing effect of FA-sul was less pronounced in femoral arteries isolated from sGCα 1 (-/-) mice compared to control mice, confirming sGC as a mediator of FA-sul dependent vasorelaxations ( Fig. 5 B) .
While big arteries like aorta play a role in conducting the blood and damping pulse pressure, smaller arteries contribute more to arterial resistance and hence blood pressure regulation [27] .
Consequentially, femoral or saphenous arteries provide a more relevant model for ex vivo tension measurements compared to large diameter arteries such as aorta. Further mechanistic investigations were therefore conducted only on femoral arteries where the FA-sul mediated relaxations were found to be maximal. Vasorelaxation pathways involving K + -channel opening were investigated by exposing femoral arteries to a high concentration of K + (Fig. 6 A) or K +channel blockers (Fig. 6 B-F) . Decreased FA-sul-induced vasorelaxation in the presence of K + and TEA confirmed the involvement of K + channels and more specifically K v -channels, as indicated by A C C E P T E D M A N U S C R I P T
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the decreased response in the presence of 4-AP ( Fig. 6 A,B,F) . Ba 2+ , apamin and glibenclamide did not affect FA-sul-induced relaxations ( Fig. 6 C,D,E).
4: Discussion
We have shown for the first time that the phenolic acid conjugate FA-sul, as present in circulation following consumption of phenolic-rich food, is more active as an ex vivo vasorelaxant and in vivo blood pressure lowering compound compared to the parent aglycone FA. Since FA is a major phenolic present in human diet, the daily intake can exceed 100 mg [28] , supporting high circulating FA-sul concentrations. Indeed, phase II conjugates constitute a significant portion of the bioavailable FA present in plasma [8, 9, 14, 15, 17, 18] and urine [11, 18] and could contribute to beneficial health effects of FA-rich foods. Although glucuronidation and sulfation generally decrease biological activity [29] , we showed that sulfation of FA enhanced its bioactivity, a unique finding similar to the K + -channel-dependent vasodilatory activity of the circulating metabolite minoxidil sulfate, derived from the vasodilator drug minoxidil [30] .
To our knowledge, no other studies have determined cardiovascular health benefits of FA-sul in vitro, ex vivo or in vivo. Biological effects of FA on the other hand have been described. Ferulic acid at higher concentrations exhibits vasorelaxant properties in isolated rat arteries [22] [23] [24] and in vivo [21, 24, 31] in an endothelium-dependent fashion attributed to stimulation of NO production or antioxidant effects preventing NO degradation. A direct effect on vascular smooth muscle is not ruled out, although involvement of sGC is not confirmed [22, 31, 32] . The effects of FA are most prominent in pathophysiological conditions [21] [22] [23] 31] using high concentrations of 10 µM to 30 mM [22] [23] [24] 32] , which could explain the discrepancy compared to the results obtained in the current study where a normotensive model and lower concentrations were used.
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By using concentrations slightly exceeding those currently reported in plasma (226 nM [17] ), the potential of FA-sul as a blood pressure lowering compound and ex vivo vasorelaxant was demonstrated. The vasorelaxing mechanism of FA-sul could be investigated in more detail in isolated mouse arteries.
FA-sul-induced vasorelaxation was not endothelium nor NO-dependent, as indicated by the unchanged relaxation in endothelium denuded arteries or upon inhibition of NOS and COX by L-NAME and indomethacin. However, in the absence of NO, FA-sul induced relaxations were stimulated, and the effect reached significance in endothelium denuded aorta and L-NAME-treated femoral arteries. Consequentially, the potency of FA-sul was increased in the absence of NO, suggesting a role for FA-sul as a competitor to NO for its molecular target, sGC. Direct interactions between FA-sul and sGC were therefore investigated by incubation with ODQ, an sGC inhibitor that oxidizes the sGC heme, abolishing its NO sensitivity [33, 34] . FA-sul-mediated relaxation was attenuated by ODQ, and the involvement of sGC in FA-sul-mediated vasodilation in Swiss mice was further supported by the decreased response in sGCα 1 (-/-) mice femoral arteries. Catalytically active sGC is a heterodimeric haemoprotein consisting of α 1 /ß 1 or α 2 /ß 1 subunits, of which the ß 1 subunit contains the prostethic haem group [35] [36] [37] . Although the decreased response in sGCα 1 knockout mice indicates that sGC is involved, the residual activity of sGCα 2 ß 1 , whose enzymatic activity is substantial and unaffected in sGCα 1 (-/-) mice [25] , may explain the incomplete loss of tension in sGCα 1 (-/-) mice compared to wild-type animals. These observations indicate that FA-sul directly activates or stimulates sGC, enhancing the generation of the second messenger cyclic guanosine monophosphate (cGMP) [25, 34] .
Drugs that activate or stimulate sGC have been developed to treat pathologies associated with sGC activators such as cinaciguat (BAY 58-2667) and HMR-1766 can increase sGC activity even in the absence of NO and a functional haem group in sGC [34, 37] . This is of great interest since sGC activators are still effective when sGC has become unresponsive due to haem oxidation by increased oxidative stress, as is the case in diabetes, arterial hypertension, atherosclerosis and obesity [35, 39] . Since oxidation of the ferrous haem cofactor by ODQ [34] results in almost complete abrogation of the effects of FA-sul, and the potency of FA-sul does not increase when the haem-moiety is oxidized, as is the case for most sGC activators [40] , haem-independent sGC activator activity of FA-sul is unlikely. Our data therefore indicate that FA-sul causes a haemdependent activation of sGC, but further mechanistic studies are required to confirm this hypothesis.
As a consequence of their major role in blood pressure regulation [41, 42] and participation in downstream sGC signaling [42] [43] [44] , K + -channels could be involved in the response to FA-sul.
Nonspecific K + -channel blockade by TEA and 120 mM K + resulted in decreased response to FAsul, thus confirming that FA-sul acts through K + -channel opening. By using inhibitors targeting specific K + -channel subtypes, we observed a decreased response in the presence of 4-AP, supporting K v -channel gating as a response to FA-sul. Since sGC inhibition was very effective in our setup and the K v -channels are activated in the downstream signaling cascade of sGC in rat arteries [45, 46] , indirect effects of FA-sul downstream of sGC were possible although direct activation of K + -channels by FA-sul could not be excluded. For example, minoxidil sulfate possibly acts by induction of K + -channel mediated activity through increased intracellular Ca 2+ , cGMPdependent protein kinase (cGK) mediated enhancement of K Ca + -channels sensitivity to Ca 2+ [47] or direct sulfation of a protein subunit in K + -channels [48] . Similar mechanisms could be involved in the FA-sul mediated response, but they were not investigated in this study.
The magnitude of inhibition by TEA and K + exceeded that of 4-AP, suggesting that other potassium channels were involved. However, inhibition of inward rectifying, ATP-sensitive K + -channels and
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small conductance K Ca -channels by Ba 2+ , glibenclamide and apamin was unsuccessful in our experiments, excluding them as potential mediators of FA-sul dependent vasorelaxations.
Taken together, these data indicate that FA-sul enhances sGC activity, resulting in the production of cGMP and activation of its associated signaling pathways. K v -channel opening as a consequence of FA-sul treatment results in K + efflux, hyperpolarization and inhibition of voltageoperated Ca 2+ -channels, decreased intracellular Ca 2+ followed by vasorelaxation [32, 42] . This pathway and the proposed role of FA-sul is summarized in Fig. 7 .
In conclusion, we have for the first time compared the vasorelaxing potential of FA and FA-sul in three types of isolated mouse arteries and in vivo in anesthetized mice and identified FA-sul as a potent vasorelaxing and blood pressure-lowering compound. Our data demonstrate that sGC and 
